Neuropathology of dementia in Parkinson's disease: A prospective, community‐based study

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Annals of Neurology

• Publication date

  2005-11-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/ana.20635PMID 16240351
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Are Parkinson’s Disease with dementia and Dementia with lewy Bodies the Same Entity?

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

  2003cited by this paper
• Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response.

  2002cited by this paper
• Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease

  2002cited by this paper
• Cortical Lewy body pathology in the diagnosis of dementia

  2001cited by this paper
• Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease

  2000cited by this paper
• Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease

  2000cited by this paper
• Diagnostic criteria for Parkinson disease.

  1999cited by this paper
• The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary.

  1997cited by this paper
• Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

  1997cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)

  1996cited by this paper
• The epidemiology of Parkinson's disease in the county of Rogaland, Norway

  1995cited by this paper
• Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence

  1994cited by this paper
• The present state of people who survived the holocaust as children

  1994cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• Lewy body prevalence in the aging brain: relationship to neuropsychiatric disorders, Alzheimer-type pathology and catecholaminergic nuclei.

  1990cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies

  2025cites this paper
• Apolipoprotein E genotypes and amyloid burden associated with cognitive decline in non-demented Parkinson's disease patients: A preliminary analysis.

  2025cites this paper
• The effect of Amyloid and Tau Co-pathology on disease progression in Lewy body dementia: A systematic review.

  2024cites this paper
• Cardiovascular dysautonomia and cognitive impairment in Parkinson's disease (Review)

  2024cites this paper
• Patterns of regional cerebral hypoperfusion in early Parkinson's disease: Clinical implications.

  2024cites this paper
• Comparative mapping of single-cell transcriptomic landscapes in neurodegenerative diseases

  2024cites this paper
• Binding site prediction between lysozyme and glucose-regulated protein 78, a hope to fight amyloidosis

  2024cites this paper
• Misfolded protein deposits in Parkinson’s disease and Parkinson’s disease-related cognitive impairment, a [11C]PBB3 study

  2024cites this paper
• Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer’s disease-associated biomarkers alterations among de novo Parkinson’s disease patients: a prospective cohort study

  2023cites this paper
• Formation of templated inclusions in a forebrain α-synuclein mouse model is independent of LRRK2

  2023cites this paper
• Investigation of Inflammation in Lewy Body Dementia: A Systematic Scoping Review

  2023cites this paper
• Formation of templated inclusions in a forebrain α-synuclein mouse model is independent of LRRK2

  2023cites this paper
• Neuropsychiatrische symptomen bij de ziekte van Parkinson: een gevalsbeschrijving

  2022cites this paper
• In Vivo 18F‐Florzolotau Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia

  2022cites this paper
• Impact of Subthalamic Nucleus Stimulation on Urinary Dysfunction and Constipation in Parkinsons Disease

  2022cites this paper
• Analysis of the enzymatic degradation of lysozyme fibrils using a combination method of non-denaturing gel electrophoresis and double staining with Coomassie Brilliant Blue G-250 and R-250 dyes

  2022cites this paper
• Management of psychiatric and cognitive complications in Parkinson’s disease

  2022cites this paper
• Neocortical Lewy Body Pathology Parallels Parkinson's Dementia, but Not Always

  2022cites this paper
• Cortical excitability changes as a marker of cognitive impairment in Parkinson's disease.

  2022cites this paper
• Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis

  2022cites this paper
• Morphological basis of Parkinson disease-associated cognitive impairment: an update

  2022cites this paper
• Effect of cerebral small vessel disease on cognitive impairment in Parkinson's disease

  2022cites this paper
• Neuropathological substrates of cognition in Parkinson's disease.

  2022cites this paper
• GBA-associated PD: chances and obstacles for targeted treatment strategies

  2022cites this paper
• Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with de novo Parkinson’s disease

  2022cites this paper
• Nonmotor problems in Parkinson disease

  2021cites this paper
• Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors

  2021cites this paper
• Alpha-Synuclein and Cognitive Decline in Parkinson Disease

  2021cites this paper
• A More Homogeneous Phenotype in Parkinson's Disease Related to R1441G Mutation in the LRRK2 Gene

  2021cites this paper
• Demencia con cuerpos de Lewy

  2021cites this paper
• Characteristics of Parkinson’s Disease in Patients with and without Cognitive Impairment

  2021cites this paper
• Contribution of Alzheimer's disease neuropathologic change to the cognitive dysfunction in human brains with Lewy body-related pathology.

  2020cites this paper
• Neuropathological and Biomarker Findings in Parkinson’s Disease and Alzheimer’s Disease: From Protein Aggregates to Synaptic Dysfunction

  2020cites this paper
• GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds

  2020cites this paper
• Prevalence and clinical associations of tau in Lewy body dementias: A systematic review and meta-analysis.

  2020cites this paper
• Chronic α-Synuclein Accumulation in Rat Hippocampus Induces Lewy Bodies Formation and Specific Cognitive Impairments

  2020cites this paper
• Neuroinflammation and protein pathology in Parkinson’s disease dementia

  2020cites this paper
• LRRK2 and Protein Aggregation in Parkinson’s Disease: Insights From Animal Models

  2020cites this paper
• Cognitive impairment in Parkinson's disease: A clinical and pathophysiological overview.

  2020cites this paper
• NEUROPSYCHOLOGICAL CORRELATES OF STRIATAL DOPAMINERGIC DYSFUNCTION IN PARKINSON’S DISEASE

  2019cites this paper
• Seeding of protein aggregation causes cognitive impairment in rat model of cortical synucleinopathy

  2019cites this paper
• Ginsenoside Rb1 prevents MPTP-induced changes in hippocampal memory via regulation of the α-synuclein/PSD-95 pathway

  2019cites this paper
• Neuroimaging in Parkinson’s disease dementia: connecting the dots

  2019cites this paper
• The biology of cognitive decline and reduced survival in Parkinson disease : prognostic factors in a population-based cohort

  2019cites this paper
• OP-BRCM190009 1..17

  2019cites this paper
• Entorhinal Cortex Atrophy in Early, Drug-naive Parkinson’s Disease with Mild Cognitive Impairment

  2019cites this paper
• Neuropathology of dementia in patients with Parkinson’s disease: a systematic review of autopsy studies

  2019cites this paper
• The center of olfactory bulb‐seeded α‐synucleinopathy is the limbic system and the ensuing pathology is higher in male than in female mice

  2019cites this paper
• Diffuse Lewy body disease.

  2019cites this paper
• Neurocomputational models of corticostriatal interactions in action selection

  2019cites this paper
• Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but 'failure to fit' is highly dependent on staging system applied.

  2019cites this paper
• Resting-state fMRI in Parkinson's disease patients with cognitive impairment: A meta-analysis.

  2019cites this paper
• Regional neuropathology distribution and verbal fluency impairments in Parkinson's disease.

  2019cites this paper
• Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease

  2019cites this paper
• The Role of the Neuropsychologist in Deep Brain Stimulation

  2019cites this paper
• The Neuropsychiatry of Parkinson Disease: A Perfect Storm.

  2019cites this paper
• Neurodegenerative Erkrankungen

  2019cites this paper
• Hormones of energy homeostasis : linking weight loss and cognition in Parkinson's disease?

  2018cites this paper
• Critical appraisal of pathology transmission in the &agr;‐synuclein fibril model of Lewy body disorders

  2018cites this paper
• Association between White Matter Lesions and Non-Motor Symptoms in Parkinson Disease

  2018cites this paper
• Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach

  2018cites this paper
• Longitudinal magnetic resonance imaging of cognitive impairment in Parkinson’s disease

  2018cites this paper
• Distinct manifestation of cognitive deficits associate with different resting-state network disruptions in non-demented patients with Parkinson’s disease

  2018cites this paper
• Neuropathology of Parkinson disease.

  2018cites this paper
• Prospective Memory Impairment in Parkinson Disease without Dementia: Cognitive Mechanisms and Intervention

  2018cites this paper
• Amyloid-β and Parkinson’s disease

  2018cites this paper
• Cognitive impairment and dementia in Parkinson’s disease

  2017cites this paper
• Major Depressive Disorder [ 7 ] , Addiction [ 8 ] , Akinetic Mutism [ 9 ] , Alcohol Abuse [ 10 ]

  2017cites this paper
• Cognitive impairment in Glucocerebrosidase (GBA)‐associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles

  2017cites this paper
• CT, MRI, SPECT, and PET in DLB

  2017cites this paper
• The Lewy Body Dementias: Dementia with Lewy Bodies and Related Syndromes

  2017cites this paper
• Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal τ and Aβ as well as dementia-risk in Parkinson's disease.

  2017cites this paper
• Regional Overlap of Pathologies in Lewy Body Disorders

  2017cites this paper
• Cognitive Rehabilitation in Parkinson's Disease: Is it Feasible?

  2017cites this paper
• Rendimiento cognitivo poblacional en enfermedad de Parkinson y temblor esencial: ¿qué ocurre en ausencia de demencia?

  2017cites this paper
• Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias.

  2017cites this paper
• Nonmotor Symptoms and Natural History of Parkinson's Disease: Evidence From Cognitive Dysfunction and Role of Noninvasive Interventions.

  2017cites this paper
• Comparative Patient Satisfaction and Feasibility of a Pilot Parkinson’s Disease Enrichment Program

  2017cites this paper
• Imaging the Nonmotor Symptoms in Parkinson's Disease.

  2017cites this paper
• Quantitative Electroencephalography and genetics as biomarkers of dementia in Parkinson’s disease

  2017cites this paper
• Biomarkers in dementia with Lewy bodies

  2016cites this paper
• A Comparative Study of Delayed Verbal and Visuospatial Recall, and Inhibition in Parkinson's Disease Dementia

  2016cites this paper
• Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia

  2016cites this paper
• TITLE: Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases Running Head: Neuropathology of dementia in the Lewy body disease spectrum AUTHORS:

  2016cites this paper
• Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases

  2016cites this paper
• Alpha‐Synuclein as a Biomarker for Parkinson's Disease

  2016cites this paper
• Imaging as a Diagnostic Tool in Parkinson’s Disease

  2016cites this paper
• The contribution of white matter lesions (WML) to Parkinson's disease cognitive impairment symptoms: A critical review of the literature.

  2016cites this paper
• Assessing medication role on neuropathological findings in Parkinson's disease

  2016cites this paper
• Biomarkers for dementia and mild cognitive impairment in Parkinson's disease

  2016cites this paper
• Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency

  2016cites this paper
• Long term clinical disease progression in patients with Parkinson’s disease after STN Deep Brain Stimulation

  2016cites this paper
• Evaluation and Management of Dementia

  2016cites this paper
• The association between SBP and mortality risk differs with level of cognitive function in very old individuals

  2016cites this paper
• Parkinsonism and Related Disorders

  2016cites this paper
• Étude comparative de la mémoire de source et des faux souvenirs dans la maladie d’Alzheimer et la maladie de Parkinson avec et sans démence

  2016cites this paper
• Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia

  2016influential citation
• Neuropathological basis of nonmotor manifestations of Parkinson's disease

  2016cites this paper
• Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson’s Disease

  2016cites this paper
• Parkinson Disease and Dementia

  2016cites this paper